Polymorphisms of drug-metabolizing enzymes CYP1A1, GSTT and GSTP contribute to the development of diffuse large B-cell lymphoma risk in the Saudi Arabian population

被引:34
作者
Al-Dayel, Fouad [1 ,2 ,3 ]
Al-Rasheed, Maha [1 ]
Ibrahim, Muna [1 ]
Bu, Rong [1 ]
Bavi, Prashant [1 ]
Abubaker, Jehad [1 ]
Al-Jomah, Naif [1 ]
Mohamed, Gamal H. [1 ]
Moorji, Azadali [1 ]
Uddin, Shahab [1 ]
Siraj, Abdul K. [1 ]
Al-Kuraya, Khawla [1 ]
机构
[1] King Faisal Specialist Hosp & Res Ctr, Human Canc Genom Res Ctr, KFNCCC&R, Riyadh 11211, Saudi Arabia
[2] King Faisal Specialist Hosp & Res Ctr, Dept Pathol, Riyadh 11211, Saudi Arabia
[3] King Faisal Specialist Hosp & Res Ctr, Lab Med, Riyadh 11211, Saudi Arabia
关键词
xenobiotic genes; polymorphism; diffuse large B-cell lymphoma; SNP;
D O I
10.1080/10428190701704605
中图分类号
R73 [肿瘤学];
学科分类号
100214 [肿瘤学];
摘要
The last four decades have seen significant increase in the incidence of non-Hodgkin lymphoma (NHL) as a possible result of increasing environmental carcinogens exposure. Based on the increasing evidence for the association between carcinogen-exposure-related cancer risk and xenobiotic gene polymorphisms, we have undertaken a hospital based case-control study on xenobiotic gene polymorphisms in Saudi individuals with a diagnosis of diffuse large B-cell lymphoma (DLBCL). Polymorphisms in five genes (CYP1A1, GSTT1, GSTP1, GSTM1, and NQO1) were characterized in 182 individuals with DLBCL and 513 normal controls using PCR-RFLP method. The CYP1A1*2C (p=0.011, OR: 6.62, and 95% CI: 1.56-28.10), GSTT1 null (p0.001, OR: 11.94, 95% CI: 7.88-18.12), and GSTP1 TT genotypes (p=0.017, OR: 3.42, 95% CI 1.26-9.38) demonstrated significant association of DLBCL risk. None of the other alleles tested for proved to be significant indicators of DLBCL risk. Our findings suggest that polymorphisms of xenobiotic metabolizing enzyme genes may modify the individual susceptibility to develop DLBCL in Saudi Arabian population.
引用
收藏
页码:122 / 129
页数:8
相关论文
共 50 条
[1]
The non-Hodgkin lymphomas: A review of the epidemiologic literature [J].
Alexander, Dominik D. ;
Mink, Pamela J. ;
Adami, Hans-Olov ;
Chang, Ellen T. ;
Cole, Philip ;
Mandel, Jack S. ;
Trichopoulos, Dimitrios .
INTERNATIONAL JOURNAL OF CANCER, 2007, :1-39
[2]
Polymorphisms within glutathione S-transferase genes and initial response to glucocorticoids in childhood acute lymphoblastic leukaemia [J].
Anderer, G ;
Schrappe, M ;
Brechlin, AM ;
Lauten, M ;
Muti, P ;
Welte, K ;
Stanulla, M .
PHARMACOGENETICS, 2000, 10 (08) :715-726
[3]
[Anonymous], IARC SCI PUBLICATION
[4]
Genetic polymorphisms in human xenobiotica metabolizing enzymes as susceptibility factors in toxic response [J].
Autrup, H .
MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS, 2000, 464 (01) :65-76
[5]
Role of CYP2D6, CYP1A1, CYP2E1, GSTT1, and GSTM1 genes in the susceptibility to acute leukemias [J].
Aydin-Sayitoglu, M ;
Hatirnaz, O ;
Erensoy, N ;
Ozbek, U .
AMERICAN JOURNAL OF HEMATOLOGY, 2006, 81 (03) :162-170
[6]
BAZARBASHI S, 2004, CANC INCIDENCE REPOR
[7]
Variable drug metabolism genes in Arab population [J].
Bu, R ;
Gutiérrez, MI ;
Al-Rasheed, M ;
Belgaumi, A ;
Bhatia, K .
PHARMACOGENOMICS JOURNAL, 2004, 4 (04) :260-266
[8]
Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcγRIIIa gene [J].
Cartron, G ;
Dacheux, L ;
Salles, G ;
Solal-Celigny, P ;
Bardos, P ;
Colombat, P ;
Watier, H .
BLOOD, 2002, 99 (03) :754-758
[9]
Chan WC, 1997, BLOOD, V89, P3909
[10]
Association of NAT and GST polymorphisms with non-Hodgkin's lymphoma:: a population-based case-control study [J].
Chiu, BCH ;
Kolar, C ;
Gapstur, SM ;
Lawson, T ;
Anderson, JR ;
Weisenburger, DD .
BRITISH JOURNAL OF HAEMATOLOGY, 2005, 128 (05) :610-615